Our People

At Myriad, our passion for patients drives everything we do – on the job and in the community.

Our Products

Myriad is answering patients’ most pressing questions about disease.

Our Pipeline

Myriad has the deepest diagnostic pipeline across the disease spectrum.

The Science

At Myriad, we’re leveraging our unique expertise in sequencing and analysis to better understand human disease.

myRisk® Hereditary Cancer

The Myriad myRisk® Hereditary Cancer test is a 28-gene panel that identifies an elevated risk for eight important cancers.

Prolaris®

Prolaris®

Prolaris aids healthcare professionals in predicting prostate cancer aggressiveness and disease progression.

GeneSight®

GeneSight meets a significant unmet clinical need and is the leading product for psychotropic drug selection.

Breaking News

Thursday, October 19, 2017

GeneSight® Shown to Statistically Significantly Improve Generalized Anxiety Disorder Treatment Response and Decrease Benzodiazepine Use

Wednesday, October 18, 2017

Myriad's BRACAnalysis CDx® Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Lynparza® (olaparib) in Metastatic Breast Cancer
Read News

Vectra® DA

Vectra DA is an advanced blood test that measures rheumatoid arthritis disease activity.

EndoPredict®

Helping Doctors guide ER+, HER2- early-stage breast cancer patients toward the appropriate treatment decision.

Hereditary Cancer Quiz

Take a 30-second quiz to help you find out if you’re at risk of hereditary cancer.

Events

Myriad Genetics Fourth Quarter Fiscal 2017 Financial Results Conference Call
Aug 8, 2017
4:30 PM ET

Listen to Webcast

Myriad Blog

View Blog